Patents Examined by Joseph Spangler
  • Patent number: 12152264
    Abstract: Disclosed are a phosphinothricin dehydrogenase mutant, a recombinant bacterium and a one-pot multi-enzyme synchronous directed evolution method. The phosphinothricin dehydrogenase mutant, with an amino acid sequence as shown in SEQ ID No.1, is obtained by mutating alanine at position 164 to glycine, arginine at position 205 to lysine, and threonine at position 332 to alanine in a phosphinothricin dehydrogenase derived from Pseudomonas fluorescens. The recombinant bacterium is obtained by introducing a gene encoding the phosphinothricin dehydrogenase mutant into a host cell. The host cell can also incorporate a gene encoding a glucose dehydrogenase or a gene encoding a formate dehydrogenase to undergo synchronous directed evolution to achieve double gene overexpression. The one-pot multi-enzyme synchronous directed evolution method of the present invention can screen recombinant bacteria with greatly improved activity.
    Type: Grant
    Filed: December 26, 2020
    Date of Patent: November 26, 2024
    Assignee: ZHEJIANG UNIVERSITY OF TECHNOLOGY
    Inventors: Yaping Xue, Feng Cheng, Jumou Li, Qinghua Li, Yuguo Zheng, Shuping Zou, Jianmiao Xu
  • Patent number: 12129465
    Abstract: Provided herein are compositions and methods comprising mutated coronavirus ā€œSā€ spike proteins or receptor binding domains thereof that have an increased expression level, yield and stability compared to its corresponding native or wild-type coronavirus spike protein under the same expression, culture or storage conditions. These mutated spike proteins can be used for generating a protein-based vaccine against one or more coronaviruses.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: October 29, 2024
    Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON RESEARCH CENTER
    Inventors: Daniel Ellis, Neil King, Jesse Bloom, Tyler Starr, Allison Greaney